(Reuters) -The Centers for Medicare & Medicaid Services said on Friday that it did not move forward with a proposal put forth ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Hitting a plateau after a steady run of weight loss has derailed many health and ... researchers from the University of Southern Denmark (USD) made a surprise genetic discovery, identifying ...

Can a weight-loss drug become a weapon of war? Once, that question might have seemed absurd. No longer. Earlier this year, when US President Donald Trump offered to buy Greenland from Denmark, online ...

The Phase 1a trial is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of AT-7687. It will be conducted in healthy lean and ...

Headquarters of pharmaceutical company Novo Nordisk in Copenhagen, Denmark, on Sept ... overweight and obese people achieve sustained weight loss. Novo said it will detail results from both ...

Although the trial results failed to meet Novo Nordisk’s projection of 25% weight loss, the Denmark-based drugmaker said it plans to seek regulatory approval of CagriSema in early 2026.

Denmark, on March 8, 2024.Carsten Snejbjerg/Bloomberg—Getty Images Senior Correspondent There’s no question that the wildly popular injectable weight-loss drugs help people drop pounds ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...